Yes, I agree, if given at an early stage, it could potentially perform even better when used as first-line therapy in less sick patients. However the drawback with less sick patients is that it is also very possible that side effects and toxicity may be more significant, due to patients over all health status. So yes, enhanced possibility of efficacy + enhanced risk of toxicity. All of this is to say, Azer Cell would need to confrim efficacy/safety through clinical trials to ensure its safety and effectiveness in that first -in line setting.
With first line therapy offering 60% cure rate and Azer cell 57% cure rate it aint gonna magically be put into earlier lines , or be pushed through (w/o trials) or takeover all of other lines of therapy because it so amazing.
To get to third line therapy - commercially it is gonna take - all of this year and most of next year (noting the rate of enrolment thus far) To get to second line (if at all) it is going to take - another two years after that. To get to first line (if at all) another two years on top of that. That would at lightspeed - with nothing going wrong.
IMU Price at posting:
4.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)